The race to find a COVID-19 vaccine

As researchers rush to develop a drug against coronavirus, and thousands sign up to participate in clinical trials, what are the technical, ethical and political obstacles to coming up with an effective and safe vaccine quickly?
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news

Related Links:

ET has gathered that China is taking advantage of Covid to exploit developing and least developed countries across sectors from pharma to trade. Last month there were reports that China may run the second phase trial of the coronavirus vaccine in Bangladesh.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
As Foster City-based Gilead Sciences moves forward with remdesivir and other Bay Area companies pursue new or repurposed drugs and vaccines against Covid-19 and the coronavirus that causes the disease, NIAID chief Dr. Tony Fauci talked in a webinar with Dr. Lloyd Minor, Stanford University's medical school dean.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Some evidence suggests the triple MMR jab, given to millions of British children since its introduction in the UK in 1988, could be a powerful weapon in the battle against coronavirus.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Recently, Lori Reilly, Chief Operating Officer at PhRMA, participated in a podcast with the Counsel of State Governments (CSG) to discuss the important work the biopharmaceutical industry is doing to combat COVID-19.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Research and Development Vaccines Coronavirus Source Type: news
Matt Hancock said the Government had procured enough jabs to vaccinate a record-breaking number of Britons on the NHS this winter. A flu outbreak and rising Covid cases would cripple the NHS.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Authors: Jiang ZZ, He C, Wang DQ, Shen HL, Sun JL, Gan WN, Lu JY, Liu XT Abstract In December 2019, an outbreak of coronavirus infection emerged in Wuhan, Hubei Province of China, which is now named Coronavirus Disease 2019 (COVID-19). The outbreak spread rapidly within mainland China and globally. This paper reviews the different imaging modalities used in the diagnosis and treatment process of COVID-19, such as chest radiography, computerized tomography (CT) scan, ultrasound examination, and positron emission tomography (PET/CT) scan. A chest radiograph is not recommended as a first-line imaging modality for COVI...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Scientists at the University of Melbourne found that a type of immunity produced through antibodies was only 'modest' in a study on 41 people, and said a vaccine is needed to protect people in future.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
King's College London scientists looked at the immune response of more than 90 patients and healthcare workers. The study suggests a vaccine for coronavirus may have to be reformulated yearly.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Funding Opportunity PAR-20-256 from the NIH Guide for Grants and Contracts. The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAIDs vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
AbstractCoronavirus disease 2019 (COVID ‐19), caused by the SARS‐CoV‐2 novel coronavirus, has spread worldwide causing high fatality rates. Neither a vaccine nor specific therapeutic approaches are available, hindering the fight against this disease and making better understanding of its pathogenesis essential. Despite similarities between SARS‐CoV‐2 and SARS‐CoV, the former has unique characteristics which represent a great challenge to physicians. The mechanism of COVID‐19 infection and pathogenesis is still poorly understood. In the present review, we highlight possible pathways involved in the pathogenesi...
Source: Pharmacology Research and Perspectives - Category: Drugs & Pharmacology Authors: Tags: REVIEW Source Type: research
More News: Clinical Trials | Coronavirus | COVID-19 | Health | Medical Ethics | Politics | Vaccines